17%The following table presents Endo's unaudited condensed consolidated cash flow data for the twelve months ended December 31, 2010 and December 31, 2009:
Endo Pharmaceuticals Holdings Inc.
Condensed Consolidated Cash Flow Data (unaudited)
(in thousands)Twelve Months EndedDecember 31,2010
2009Net cash provided by operating activities
295,406Net cash used in investing activities
(245,509)Net cash used in financing activities
(117,128)Net increase (decrease) in cash and cash equivalents
$ (67,231)Cash and cash equivalents, beginning of period$
775,693Cash and cash equivalents, end of period
708,462Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individuall
|SOURCE Endo Pharmaceuticals|
Copyright©2010 PR Newswire.
All rights reserved